2014
DOI: 10.1126/science.1251546
|View full text |Cite
|
Sign up to set email alerts
|

Enabling the genomic revolution in Africa

Abstract: H3Africa is developing capacity for health-related genomics research in Africa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
276
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 387 publications
(283 citation statements)
references
References 10 publications
2
276
0
Order By: Relevance
“…Most of the funding for African research comes from outside Africa, such as from the National Institutes of Health, Wellcome Trust and the European Union-Africa partnerships. [7,8] The African Union has previously committed 1% of its GDP to research, while local governments only spend a fraction of that on health research. [9] We ourselves have secured funding from the HIV Trust (UK) and SA's National Research Foundation (NRF).…”
Section: Research and Fundingmentioning
confidence: 99%
“…Most of the funding for African research comes from outside Africa, such as from the National Institutes of Health, Wellcome Trust and the European Union-Africa partnerships. [7,8] The African Union has previously committed 1% of its GDP to research, while local governments only spend a fraction of that on health research. [9] We ourselves have secured funding from the HIV Trust (UK) and SA's National Research Foundation (NRF).…”
Section: Research and Fundingmentioning
confidence: 99%
“…This study is funded by the National Institutes of Health as part of the Human Heredity and Health in Africa Consortium (H3Africa) [17,18]. AWI-Gen’s main purpose is to further understand the prevalence of cardiometabolic disease (CMD), associated risk factors, regional burden, and to explore gene–gene and gene–environment interactions that contribute to disease risk.…”
Section: Introductionmentioning
confidence: 99%
“…AWI-Gen deliberately examines older adults aged between 40–60 years, a period during which CMD is most likely to present, and therefore enhances its ability to discover associations between CMD outcomes and risk factors, including genetic susceptibility. In line with the H3Africa mandate, there is a focus on assessing genomic associations with common diseases among Africans [17].
10.1080/16549716.2018.1507133-F0001Figure 1.Conceptual framework for Phase 1 of the AWI-Gen study.
…”
Section: Introductionmentioning
confidence: 99%
“…37 Current funding is increasing emphasis on inclusion of non-European populations in ongoing genetic analysis, including the Human Heredity and Health in Africa Initiative, jointly funded by National Institutes of Health and the Wellcome Trust. 44 Once genetic markers have been identified, thought must be given to the optimal strategy for incorporating multiple loci into CVD risk prediction because currently identified SNPs have small effect sizes (odds ratios in the range of ≤1.2). Using a single SNP for prediction is ineffective, as demonstrated by analysis of the 9p21.3 locus.…”
Section: Genetic Markers Of Riskmentioning
confidence: 99%